ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013
Building a personalized medicine infrastructure at a major cancer center.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.Disease markers · 2017Trial
- Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.Journal of hematology & oncology · 2014Trial
- Molecular Tumor Board-Directed Treatment for Patients with Advanced-Stage Solid Tumors: A Case-Control Real-World Study.Current oncology (Toronto, Ont.) · 2026Observational
- Computational-Based Polyphenol Therapy for Nonsmall Cell Lung Cancer: Naringin Coamorphous Systems for Solubility and Bioavailability Enhancement.Molecular pharmaceutics · 2024Article
- Review
- Genetic Diversity Landscape in African Population: A Review of Implications for Personalized and Precision Medicine.Pharmacogenomics and personalized medicine · 2024Review
- Learning from cancer to address COVID-19.Biologia futura · 2023Review
- MatchMiner: an open-source platform for cancer precision medicine.NPJ precision oncology · 2022Article
- Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital.Journal of personalized medicine · 2021Review
- Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey.JCO precision oncology · 2021Article
- Precision Genomic Practice in Oncology: Pharmacist Role and Experience in an Ambulatory Care Clinic.Pharmacy (Basel, Switzerland) · 2020Article
- Article
- Precision Oncology Decision Support: Current Approaches and Strategies for the Future.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Review
- Physician Experiences and Understanding of Genomic Sequencing in Oncology.Journal of genetic counseling · 2018Article
- LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways.RSC advances · 2018Article
- Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Review
- Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer.Scientific reports · 2017Article
- Observational
- Personalized characterization of diseases using sample-specific networks.Nucleic acids research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Our understanding of cancer biology is rapidly increasing, as is the availability and affordability of high throughput technologies for comprehensive molecular characterization of tumors and the individual's own genetic makeup. Thus, the time is right to implement personalized molecular medicine for all patients with cancer. Personalized approaches span the full cancer care spectrum from risk stratification to prevention, screening, therapy, and survivorship programs. Several molecular therapeutics have entered clinical trials creating a huge opportunity to couple genomic markers with this emerging drug tool kit. The number of patients managed in major cancer centers creates a challenge to the implementation of genomic technologies required to successfully deliver on the promise of personalized cancer care. This requires a major investment in infrastructure to facilitate rapid deployment of multiplex, cost-effective, and tissue-sparing assays relevant across multiple tumor lineages in the Clinical Laboratory Improvement Amendments (CLIA) environment. Efforts must be made to ensure that assays are accessible to patients most likely to be enrolled onto molecular-marker-driven trials and that the tests are billable and payable, which will make them accessible to a wide range of patients. As the number of patients and aberrations increase, it will become critical to provide decision support for genomic medicine. Institutional commitment is needed to optimize accessibility and quality of research biopsies and to facilitate novel personalized cancer therapy trials. This article will focus on the challenges and opportunities that accompany the building of infrastructure for personalized cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.